Ubs Oconnor LLC Morphic Holding, Inc. Transaction History

Ubs Oconnor LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $502,419 - $908,979	14,635 New	14,635 $839 Million
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $333,734 - $624,741	-12,831 Reduced 29.58%	30,552 $1.15 Million
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $165,334 - $208,004	6,849 Added 18.75%	43,383 $0
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $66,690 - $100,109	-3,000 Reduced 7.59%	36,534 $1.03 Billion
Q2 2022 Aug 12, 2022	BUY	$19.74 - $43.01 $89,501 - $195,007	4,534 Added 12.95%	39,534 $857,000
Q1 2022 May 16, 2022	BUY	$36.25 - $52.02 $1.27 Million - $1.82 Million	35,000 New	35,000 $1.41 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.